Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan NV

www.mylan.com

Latest From Mylan NV

Perrigo Positioned To Prosper From Potential Amazon OTC Product Play

CEO John Hendrickson says Perrigo would work with Amazon to develop its own private label OTC line and would not expect to lose existing customers. At a recent investor conference, he said Amazon’s commitment to the OTC category would help grow the market, not take market share from other firms.

Consumer Business Strategies

Deal Watch: AstraZeneca Offloads US Anesthesiology Portfolio To Aspen

Merck adds to its immuno-oncology R&D heft with purchase of Rigontec, while Allergan will collaborate with Lyndra to produce once-weekly drugs for Alzheimer’s disease.

Deals M & A

Mylan Calls Allergan Restasis Patent Deal A 'Desperate Tactic'

Allergan's potential Restasis generic rival wasted no time attacking the company in court documents over the controversial deal Allergan signed with a Native American tribe to thwart generic competition.

Intellectual Property Legal Issues

Indian Generics Firms Must Shift Gears For Third Wave, Says Lupin MD

Indian firms must transition from “plain-vanilla” generics to more complex products, including biosimilars, if they want to continue growing. However, returns from the sector’s so-called Third Wave will be some time coming, warns Lupin’s managing director Nilesh Gupta.

Generic Drugs Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register